Neoleukin Therapeutics develops immunotherapies for various disorders such as cancer, inflammation and autoimmunity using protein design technology. Their leading candidate product is NL-201, which mimics the therapeutic activity of interleukin to combat cancer growth. The company, previously known as Aquinox Pharmaceuticals, was founded in 2003 and is based in Seattle, Washington.